|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 2/01/19 Menlo Therapeutics Inc. S-3 6:1.5M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: S-3 Registration Statement for Securities Offered HTML 303K
Pursuant to a Transaction
2: EX-1.2 Underwriting Agreement HTML 185K
3: EX-4.4 Instrument Defining the Rights of Security Holders HTML 217K
4: EX-5.1 Opinion re: Legality HTML 34K
6: EX-23.1 Consent of Experts or Counsel HTML 6K
5: EX-12.1 Statement re: Computation of Ratios HTML 9K
EXHIBIT 12.1
Menlo Therapeutics Inc.
Computation of Ratio of Earnings to Fixed Charges
(unaudited - in thousands)
|
|
Years Ending December 31, |
|
Nine Months Ending |
||||
|
|
2017 |
|
2016 |
|
2015 |
|
|
|
Ratio of earnings to fixed charges |
* |
|
* |
|
* |
|
* |
|
* |
We did not record earnings for the years ended December 31, 2017, 2016 or 2015 or the nine months ended September 30, 2018. Accordingly, our earnings were insufficient to cover fixed charges for such periods and we are unable to disclose a ratio of earnings to fixed charges for such periods. The dollar amount of the deficiency in earnings available for fixed charges for the years ended December 31, 2017, 2016, and 2015 and for the nine months ended September 30, 2018 was $29.1 million, $14.1 million, $4.6 million, and $33.9 million, respectively. |
| This ‘S-3’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/1/19 | |||
| 9/30/18 | 10-Q | |||
| 12/31/17 | 10-K | |||
| 12/31/16 | ||||
| 12/31/15 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/20/21 VYNE Therapeutics Inc. 10-K/A 12/31/20 14:773K 3/04/21 VYNE Therapeutics Inc. 10-K 12/31/20 98:10M 2/11/19 SEC UPLOAD¶ 4/23/19 2:45K VYNE Therapeutics Inc. |